LDV20: An Editorial Review of an Australian Listed Medicine

This editorial combines one anonymised customer experience with publicly available information from the Australian Register of Therapeutic Goods (ARTG), scientific literature and official regulatory guidance. It is intended to help readers understand how Australian Listed Medicines are regulated and how consumers can independently verify product information.

1 · Editorial scope & methodology

This is an editorial, not a clinical study. Its purpose is to walk a reader through the verification steps that a careful Australian consumer can take before purchasing a complementary medicine, and to combine those steps with one anonymised customer's day-to-day observations. Every factual claim about the product is anchored to official sources: the Therapeutic Goods Administration (TGA), the ARTG entry for LDV20 (502251), and the manufacturer pages LDV20 Official Information Center and LDV20 FAQ. Every scientific reference is anchored to PubMed, NCBI or the relevant government fact sheet.

An important methodological note. The studies cited in this article evaluated the individual ingredients — Policosanol, Berberine, Milk Thistle (silymarin) and Chromium — under various research conditions. They did not evaluate LDV20 itself. The reader should not interpret any single study cited here as evidence about LDV20's clinical performance.

2 · Background — why this editorial was commissioned

LDV20 is sold under the OZNEX brand, sponsored by Pure Australia Pty Ltd, and listed on the ARTG as an AUST L medicine. Public-facing enquiries to Pure Australia from both Australian and international readers asked two recurring questions:

1. "What does Australian Listed Medicine actually mean on a label?"
2. "How do I verify what I'm reading before I buy?"

This editorial was prepared to answer both, with one customer's day-to-day experience as a way to anchor the regulatory information in real-world language.

3 · Independent verification — what was checked before first use

Before the customer opened the LDV20 box, the following verification was performed. The same checklist can be applied by any reader:

1. The label carried "AUST L 502251". The label rule for displaying this number is set on the TGA's labelling page.
2. The ARTG record exists. The product appears at https://www.tga.gov.au/resources/artg/502251 and in the ARTG public visualisation tool.
3. The sponsor record exists. Pure Australia Pty Ltd is the listed TGA sponsor.
4. The brand line exists. The OZNEX product range is listed at https://pure-australia.com/collections/oznex.
5. Manufacturing standard is regulator-grade. LDV20, as an AUST L product, must be manufactured in a TGA-GMP licensed facility, per the TGA's Good Manufacturing Practice framework.
6. The four ingredients are individually researchable. The customer was able to look each up on PubMed and the relevant government fact sheet.

4 · Personal observations during the first month

The customer followed the directions on the LDV20 product label, kept their usual diet, and did not stack LDV20 with any other new supplement. Three personal observations were noted, with the caveat that they reflect this individual's experience only:

• Personal observation — tolerance. The customer has a sensitive stomach. No gastrointestinal discomfort was personally noticed during the first month of use. Berberine's low oral bioavailability (~0.5%) is a known research finding from a separate study and was not measured in this customer.
• Personal observation — format. The product is supplied as 120 capsules in 4 × 30-capsule blister packs, which the customer found practical. This is a product-format observation rather than a clinical observation.
• Personal observation — daily routine. The customer did not personally notice any issues while continuing their normal multivitamin routine. Individual experiences may differ, and this observation should not be interpreted as evidence regarding product interactions.

No blood-test changes, weight changes, or other clinical endpoints were measured in this experience. The Policosanol research cited later in this article (e.g. Castaño 2001) used 8- to 24-week endpoints, and that timeline has not been replicated informally here.

5 · Personal observations during continued use

By week six the customer's routine had become automatic and required no further active effort. Two general observations are shared for completeness, alongside the clarifications they require:

• Subjective "routines stabilised". The customer subjectively felt their routine had stabilised by this point. This is a customer's personal observation, not a clinical measurement, and should not be generalised to other users.
• Liver and metabolic endpoints were not measured. Published research on Milk Thistle typically focuses on chronic liver contexts (see Abenavoli 2010 and the 2024 NAFLD/NASH systematic review), and chromium research assesses normal macronutrient metabolism. The customer did not obtain a clinical panel during this period, so any claim about hepatic or metabolic outcomes is out of scope for this editorial.

6 · Published research on the four ingredients (each studied independently)

Each of LDV20's four ingredients has its own publicly available evidence base. The summaries below describe what the studies measured; they do not describe what LDV20 does, because LDV20 was not the subject of these studies.

6.1 Policosanol (formulated with 20 mg per recommended daily dose)

Policosanol is a mixture of long-chain aliphatic alcohols. LDV20 is formulated with 20 mg of Policosanol per recommended daily dose. Published studies have investigated Policosanol as an individual ingredient under various research conditions. These studies evaluated the ingredient itself rather than LDV20 specifically.

Study	Population	Reported finding (ingredient-only research)
Sugarcane-policosanol meta-analysis, 2017	Pooled RCTs, dyslipidaemia	Investigators reported reductions in total cholesterol vs placebo.
Castaño et al., 2001	Type II hypercholesterolaemia	Compared 20 mg vs 40 mg in Policosanol-only conditions.
Gouni-Berthold review, 2002	Comparative pharmacology	Reviewed Policosanol as an individual compound.
Askarpour meta-analysis, 2019	Pooled RCTs, BP	Reported blood-pressure-related findings in Policosanol-only cohorts.
Berthold et al., 2006 (Mayo Clinic Proc.)	US cohort	Reported no significant effect in their Policosanol-only study.
Dulin et al., 2006	Healthy US adults	Reported no significant effect in their Policosanol-only study.

The honest, evidence-balanced conclusion from this body of work is that Policosanol as an individual ingredient has been studied, and the strength of the evidence is geographically uneven. None of this body of work constitutes a clinical study of LDV20.

6.2 Berberine

Published studies have investigated Berberine as an individual ingredient under various research conditions. These studies evaluated the ingredient itself rather than LDV20 specifically. Key references include the 2021 PMC review, the 2020 biomolecules review, a 2025 JAMA Network Open RCT on visceral fat, and the bioavailability profile noted earlier.

6.3 Milk Thistle (silymarin)

Published studies have investigated Milk Thistle / silymarin as an individual ingredient under various research conditions. These studies evaluated the ingredient itself rather than LDV20 specifically. Key references include the StatPearls entry, a 2024 antioxidant review, the long-running Abenavoli review (2010), and the 2024 NAFLD/NASH systematic review.

6.4 Chromium

Published studies have investigated Chromium as an individual ingredient under various research conditions. These studies evaluated the ingredient itself rather than LDV20 specifically. The most authoritative single source is the U.S. National Institutes of Health Chromium Health Professional Fact Sheet, alongside the 2007 meta-analysis, the 2020 PMC review, and the 2023 RCT review.

7 · What this editorial does and does not claim

• This is not a clinical outcome report. No imaging, lipid panels, HbA1c values or hepatic enzyme results are presented. The only data in this article is the customer's personal observations.
• LDV20 is not a treatment. The TGA labelling rules limit the scope of claims that a Listed Medicine may make. As an AUST L product, LDV20 is permitted to claim support or maintenance of normal physiological function, not to diagnose, treat, cure or prevent any disease.
• Pregnancy, breastfeeding, prescription medicines, diagnosed conditions. If any of these apply, talk to a qualified healthcare professional before using any listed complementary medicine. This editor's recommendation is the same regardless.
• Studies cited reflect ingredient-level research only. All scientific studies referenced above evaluated Policosanol, Berberine, Milk Thistle or Chromium individually, not LDV20.

8 · Editorial conclusion

Based on this customer's experience, LDV20 was straightforward to use and easy to verify through Australia's therapeutic goods regulatory framework. The product's ARTG listing, Australian manufacture and publicly available ingredient information allowed the customer to make an informed purchasing decision.

What this editorial recommends, more broadly, is the verification habit: check the AUST L number on the ARTG, read the official LDV20 Information Center, look up the four ingredients on PubMed and the relevant government fact sheets, and only then decide. Individual experiences vary, and the customer's experience described here is illustrative, not normative.

9 · FAQ

Is LDV20 made in Australia?

Yes. LDV20 is an Australian Listed Medicine sponsored by Pure Australia Pty Ltd and sold under the OZNEX brand. Manufacturing occurs in a TGA-GMP-licensed Australian facility.

What does "AUST L 502251" on the LDV20 label mean?

It is the unique entry under which LDV20 is listed on the Australian Register of Therapeutic Goods. See the official record at TGA ARTG 502251 and the TGA's label rule.

What are the four ingredients in LDV20?

Policosanol (formulated with 20 mg per recommended daily dose), Berberine, Milk Thistle (silymarin), and Chromium.

How is LDV20 different from an ordinary overseas supplement?

LDV20 is supplied under Australia's listed-medicines framework, manufactured in a TGA-GMP facility, and openly listed on the ARTG. Ordinary overseas supplements do not carry that level of regulatory evidence.

Can LDV20 be taken with a daily multivitamin?

The customer in this editorial did not personally notice any issue while continuing a normal multivitamin routine; this is an individual observation and should not be interpreted as evidence regarding product interactions. If you are taking any prescription medicine, have a diagnosed condition, or are pregnant or breastfeeding, consult a qualified healthcare professional before use.

Where do I read the manufacturer's own information?

• LDV20 product page
• LDV20 Official Information Center
• LDV20 FAQ
• OZNEX full range

10 · References

Australian regulators

• Therapeutic Goods Administration (TGA)
• TGA — Listed medicines overview
• TGA ARTG — LDV20 (502251)
• TGA Sponsor record — Pure Australia
• TGA — AUST numbers on medicine labels
• TGA — Good Manufacturing Practice
• ARTG public visualisation tool

Policosanol — published research on the individual ingredient

• Gouni-Berthold et al., 2002
• Sugarcane-policosanol meta-analysis, 2017
• Castaño et al., 2001 (20 vs 40 mg)
• Askarpour meta-analysis, 2019 (BP)
• Berthold et al., 2006 (no effect)
• Dulin et al., 2006 (no effect)

Berberine — published research on the individual ingredient

• PMC review, 2021
• Biomolecules review, 2020
• JAMA Network Open RCT, 2025
• Bioavailability study

Milk Thistle (silymarin) — published research on the individual ingredient

• StatPearls — Milk Thistle (2024)
• Silymarin antioxidant review, 2024
• Abenavoli et al., 2010
• Mulrow et al., 2000 (AHRQ)
• NAFLD/NASH systematic review, 2024

Chromium — published research on the individual ingredient

• NIH ODS Chromium Fact Sheet
• Jain meta-analysis, 2007
• Chromium picolinate 2020 PMC review
• Chromium & T2D 2023 review
• StatPearls — Chromium deficiency

Pure Australia internal pages referenced in this editorial

• Pure Australia — Home
• OZNEX Collection
• LDV20 product page
• LDV20 Official Information Center
• LDV20 FAQ
• Our Story
• Pure Australia blog index

---